Sanyou Biopharmaceuticals has established a comprehensive Integrated R&D Platform aimed at the development of innovative biological drugs. This platform encompasses a wide array of services and solutions, structured around a 4C business model that integrates Contract Research Organization (CRO), Contract Development Organization (CDO), Cooperative Project Organization (CPO), and Core Reagent Solution (CRS). The company boasts a super-trillion level library capacity and offers a robust framework that includes ten functional modules, facilitating the entire drug development process from target identification to clinical sample production. This integrated approach is designed to streamline R&D efforts and enhance the efficiency of drug discovery.

In addition to its extensive service offerings, Sanyou Biopharmaceuticals emphasizes the incorporation of advanced technologies such as artificial intelligence (AI) and automation within its R&D processes. The company is committed to maintaining high standards, as evidenced by its ISO9001 Quality Management System Certification. By leveraging these innovative technologies, Sanyou aims to transform the landscape of drug development, making it more accessible and efficient for global clients engaged in the pursuit of novel biologic therapies.

China

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou is committed to bridge drug R&D and all-life-cycle manufacture supply chain, and has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS”, to accomplish the mission “to make the R&D easy for innovative biologics”.


Sanyou Biopharmaceuticals

Company Details